GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » 12-1 Month Momentum %

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) 12-1 Month Momentum % : 5.04% (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-06-08), Phoenix Biotech Acquisition's 12-1 Month Momentum % is 5.04%.

The industry rank for Phoenix Biotech Acquisition's 12-1 Month Momentum % or its related term are showing as below:

PBAX's 12-1 Month Momentum % is not ranked
in the Diversified Financial Services industry.
Industry Median: 3.92 vs PBAX: 5.04

Competitive Comparison of Phoenix Biotech Acquisition's 12-1 Month Momentum %

For the Shell Companies subindustry, Phoenix Biotech Acquisition's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's 12-1 Month Momentum % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's 12-1 Month Momentum % falls into.



Phoenix Biotech Acquisition  (NAS:PBAX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phoenix Biotech Acquisition  (NAS:PBAX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Phoenix Biotech Acquisition 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103